Irlab Therapeutics Ab Class A · OMXSTO:IRLAB_A
Irlab Therapeutics Ab Class A — Q2 2025 Earnings Presentation
23 slides from Irlab Therapeutics Ab Class A's earnings presentation, Aug 27, 2025
Slide 1: Q2 2025 Interim Report
IRLAB THERAPEUTICS Q2.2025 Interim report January – June 2024 DAVID BLIMAN, chemist, working on designing drug candidates and producing them in our laboratory. ”With strong funding and new partnerships, we can realize the potential of our unique project portfolio.” KRISTINA TORFGÅRD, CEO INTERIM REP
Slide 2: Highlights During and After Q2 2025
IRLAB THERAPEUTICS Interim report January – June 2025 Highlights during and after the second quarter 2025 NEW PATENT GRANTED FOR MESDOPETAM – EXPANDS PATENT PROTECTION IN THE US AND EXPIRES IN THE 2040S. POSITIVE PHASE I RESULTS ON IRL757 SUPPORT ONGOING DEVELOPMENT. DATA PRESENTED AT AD/PD SUPPORT
Slide 3: Comments from the CEO
IRLAB THERAPEUTICS ”Together with the team, our partners, and owners, I want to continue driving our vision to improve the lives of people with Parkinson’s and other CNS diseases – a goal we will realize through value-creating partnerships and licensing agreements that benefit both patients and shar
Slide 4: Key Milestones During and After the Quarter
IRLAB THERAPEUTICS date for the next phase of development. In the study, we identi- ration agreements based on our medical innovations. I would fied the so-called therapeutic window for the plasma levels that once again like to extend my sincere thanks to existing and new individuals need to reach t
Slide 5: IRLAB's Unique Offering and Position
IRLAB THERAPEUTICS IRLAB’s unique offering and position IRLAB discovers and develops novel treatments to transform Focused strategy the life of patients living with Parkinson’s and other CNS dis- Medicines developed by IRLAB should be able to treat people orders. Rooted in Nobel Prize-winning resear
Slide 6: R&D Update
IRLAB THERAPEUTICS R&D update “That we are now submitting an application for clinical trials in a large pan-European study with IRL757 is fantastic. The collaboration with MSRD/ Otsuka is very effective and we are now looking forward to dosing the first participants in the study in late autumn. The
Slide 7: Current Status Pirepemat
IRLAB THERAPEUTICS 1.5 million people in the eight largest markets worldwide. Pirepemat Furthermore, mesdopetam has the potential to treat other Pirepemat (IRL752) has the potential to be the first in a new class neurological diseases such as tardive dyskinesia, which repre- of drugs designed to red
Slide 8: Current Status IRL757 and IRL942
IRLAB THERAPEUTICS The patent covers the active pharmaceutical ingredient used in In collaboration with MSRD, the final phase of preparations is the ongoing clinical development of pirepemat. The new patent now underway to submit the application to the European Medi- has previously been granted in t
Slide 9: Integrative Screening Process
IRLAB THERAPEUTICS studies completed in the second quarter comparing the effects which has proven to enable the discovery of truly novel first-in- of IRL1117 and levodopa, the results show that IRL1117 provides full class compounds. The ISP methodology combines systems bio- anti-Parkinson’s effect w
Slide 10: The Group's Performance January to June 2025
IRLAB THERAPEUTICS The group’s performance January – June 2025 IRLAB Therapeutics AB, corporate identity number 556931-4692, is During the first quarter of 2025, the previous loan agreement with the parent company in a group that carries out research and devel- Fenja Capital A/S (Fenja) was terminat
Slide 11: Consolidated Income Statement
IRLAB THERAPEUTICS Consolidated income statement in summary 2025 2024 2025 2024 2024 Amounts in SEK thousand Apr-Jun Apr-Jun Jan-Jun Jan-Jun Jan-Dec Operating income Net revenue 19,532 42,777 23,892 42,777 94,628 Other operating income 269 5,320 3,966 5,320 19,455 Total income 19,801 48,097 27,858 4
Slide 12: Comprehensive Income Statement
IRLAB THERAPEUTICS Consolidated statement of comprehensive income in summary 2025 2024 2025 2024 2024 Amounts in SEK thousand Apr-Jun Apr-Jun Jan-Jun Jan-Jun Jan-Dec Result for the period –32,315 –7,057 –66,284 –46,076 -83,129 Other comprehensive income - - - - - Total result for the period -32,315
Slide 13: Consolidated Financial Position
IRLAB THERAPEUTICS Consolidated statement of financial position in summary Amounts in SEK thousand 06/30/2025 06/30/2024 12/31/2024 ASSETS Fixed assets Intangible fixed assets 46,862 46,862 46,862 Tangible fixed assets 7,560 4,369 9,793 Total fixed assets 54,421 51,230 56,654 Current assets Short-te
Slide 14: Changes in Equity
IRLAB THERAPEUTICS Consolidated statement of changes in equity in summary Retained earnings incl. total Other comprehen- Share contributed sive income Total Amounts in SEK thousand capital capital for the period equity Equity January 1, 2024 1,037 690,605 –575,478 115,764 Comprehensive income for th
Slide 15: Consolidated Cash Flows
IRLAB THERAPEUTICS Consolidated statement of cash flows in summary 2025 2024 2025 2024 2024 Amounts in SEK thousand Apr-Jun Apr-Jun Jan-Jun Jan-Jun Jan-Dec Operating activities Operating result –25,726 –5,102 –54,367 –42,738 -75,111 Adjustment for items not included in the cash flow 1,111 1,151 2,23
Slide 16: Parent Company Income Statement
IRLAB THERAPEUTICS Parent company income statement in summary 2025 2024 2025 2024 2024 Amounts in SEK thousand Apr-Jun Apr-Jun Jan-Jun Jan-Jun Jan-Dec Operating income Net revenue 1,529 1,390 2,940 2,643 5,521 Total income 1,529 1,390 2,940 2,643 5,521 Operating expenses Other external costs –2,541
Slide 17: Parent Company Comprehensive Income
IRLAB THERAPEUTICS Parent company statement of comprehensive income in summary 2025 2024 2025 2024 2024 Amounts in SEK thousand Apr-Jun Apr-Jun Jan-Jun Jan-Jun Jan-Dec Profit/loss for the period –71,743 –7,073 –81,459 –12,710–46,815 Other comprehensive income - - - - - Comprehensive income for the p
Slide 18: Parent Company Balance Sheet
IRLAB THERAPEUTICS Parent company balance sheet in summary Amounts in SEK thousand 06/30/2025 06/30/2024 12/31/2024 ASSETS Fixed assets Financial fixed assets Shares in group companies 350,320 350,320 350,320 Total fixed assets 350,320 350,320 350,320 Current assets Other receivables 4,217 48,396 27
Slide 19: Key Financial Ratios
IRLAB THERAPEUTICS Key financial ratios for the group 2025 2024 2024 2023 2022 Jan – Jun Jan – Jun Jan – Dec Jan – Dec Jan – Dec Net sales, SEK thousand 23,892 42,777 94,628 5,678 61,136 Operating profit/loss, SEK thousand -54,367 –42,738 -75,111 –180,765 -113,110 Profit/loss for the period, SEK tho
Slide 20: Other Information
IRLAB THERAPEUTICS Other information Accounting principles Segment information The group applies the Swedish Annual Accounts Act and Inter- national Financial Reporting Standards (IFRS) as adopted by the Net sales by 2025 2024 2024 EU and RFR 1 Supplementary accounting rules for groups when geograph
Slide 21: Employees, AGM, Sustainability
IRLAB THERAPEUTICS Employees In June, the Board of Directors resolved, based on the authori- During the quarter, work corresponding to 30 (31) full-time equiv- zation granted by the 2025 Annual General Meeting, on an 85 alents was performed. This work has been distributed among 32 percent guaranteed
Slide 22: Glossary
IRLAB THERAPEUTICS Glossary API API stands for Active Pharmaceutical Ingredient, and it refers to the primary ingredient in a medication that provides its therapeutic effect. CNS disorders Central Nervous System (CNS) disorders are a broad category of conditions in which the brain does not function
Slide 23: Contact Information
IRLAB THERAPEUTICS IRLAB discovers and develops a portfolio of quency in Parkinson’s disease. IRL757, transformative treatments for all stages of Par- a compound being developed for the treatment kinson’s disease. The company originates from of apathy in neurodegenerative disorders, is in Nobel Laur